Pharmaceutically acceptable acid salt of free base of GLP1 receptor agonist, and preparation method therefor
AssigneeHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
InventorsHaiwen Hu, Li Fang, Fan Hu, Xinjie Zhou, Fenfen Chen
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutically acceptable acid salts of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl) propionic acid (“OAD2”) and the preparation method thereof. The pharmaceutically acceptable acid salts of OAD2 provided herein may be useful in the treatment of various conditions and metabolic disorders including, but not limited to, type 2 diabetes.
Claims23
A crystalline form of a salt of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-phenylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoquinolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionic acid (OAD2), selected from the group consisting of the following:
- crystal form B of hydrochloride salt of OAD2 (form B),
- crystal form C of hydrochloride salt of OAD2 (form C),
- crystal form C of p-toluenesulfonate salt of OAD2 (form C),
- crystal form C of tartrate salt of OAD2 (form C),
- crystal form C of citrate salt of OAD2 (form C),
- crystal form C of glycollate salt of OAD2 (form C),
- crystal form C of methanesulfonate salt of OAD2 (form C),
- crystal form C of hydrobromide salt of OAD2 (form C),
- crystal form D of hydrobromide salt of OAD2 (form D), and
- crystal form C of sulfate salt of OAD2 (form C).
Dependencies are inferred from the claim text.